Telix Pharmaceuticals forecast revenue of up to $1.23 billion in fiscal 2025 ahead of a critical year for the ASX nuclear medicine company, which has three new cancer diagnosis products scheduled to hit the market.

Shares in Telix, which makes most of its sales from prostate cancer imaging drug Illuccix in North America, rose 14 per cent to a record high on the higher-than-expected revenue forecast as it sets itself up as a dominant global player in the market for drugs that contain radioisotopes.